Stock Ratings / Health Care / ATTO / earnings

FDMT (45) SLDB (27) IAM (49) CADL (34) ⌘ Pro Terminal →

Attovia Therapeutics Inc. (ATTO) Next Earnings Date & Expected ±12.5% Move

$15.19 -0.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $15.15

Attovia Therapeutics Inc. (ATTO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $697.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ATTO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ATTO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Attovia Therapeutics Inc. (NASDAQ: ATTO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $15.19 (-0.52% 1D, market cap $697.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ATTO ranks #435 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ATTO compare to FDMT and SLDB in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATTO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FDMT (4D Molecular Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -28.3%, cap $706.0M) and SLDB (Solid Biosciences Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $685.2M). Among the 5-stock peer group, ATTO leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ATTO?

▼

Per ATTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002058707), Attovia Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $165.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $15.15 (-0.28%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ATTO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (44/100 Composite)

🔍 WHY ATTO SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($19.5M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$14.59-4.8% Next Q

Q2 (-2Q)

Grade E$13.89-0.1% Next Q

Q3 (-1Q)

Grade D$13.88+9.4% Next Q

Current

Grade D$15.19-6.5% Hist 90D α

Trajectory: E (36) → D (44)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ATTO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ATTO currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.56) and Max Pain ($15.95) forces dealer call-delta covering toward $29.40.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ATTO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ATTO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 44%NO 56%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$1.90 Expected Swing

MODEL EARNINGS SETUP GAUGE

ATTO Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$0	$0	$0	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ATTO)

✓Walkthrough of ATTO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ATTO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.64%⚡ TESTING RESISTANCE

2026-11-02O $15.80H $15.80L $15.19C $15.19VOL 413.8K

RES: $16.29SUP: $10.05SMA50: $18.56SMA200: $18.97

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ATTO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ATTO Butterfly Map → + Track ATTO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ATTO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ATTO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ATTO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ATTO)

Health Care Rank #435 of 1016 ⚔️ FDMT vs ATTO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ATTO vs. FDMT, SLDB, IAM, CADL)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Attovia Therapeutics Inc. (ATTO) ranks #435 by composite RQD confidence (44/100, grade D) and #400 by equity capitalization ($697.1M). Within this direct 5-issuer industry benchmark cohort, ATTO leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 49/100 (D) compared with ATTO at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ATTO ACTIVE Attovia Therapeutics Inc.	D	44/100	—	—	—	-0.52%	$697.1M	Benchmark Subject
FDMT 4D Molecular Therapeutics Inc.	D	45/100	—	—	-28.3%	-6.89%	$706.0M	/fdmt-vs-atto →
SLDB Solid Biosciences Inc.	E	27/100	—	—	-35.0%	-2.97%	$685.2M	/sldb-vs-atto →
IAM Iambic Therapeutics Inc.	D	49/100	—	—	—	-5.95%	$676.9M	/iam-vs-atto →
CADL Candel Therapeutics Inc.	E	34/100	—	—	-35.0%	-3.70%	$661.9M	/cadl-vs-atto →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002058707

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Attovia Therapeutics Inc. (ATTO) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ATTO closed FY2025 with $165.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$165.9M	—

3. ATTO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ATTO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does ATTO compare to FDMT and SLDB in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for ATTO?

Where is ATTO trading relative to its 50-day, 200-day, and 52-week technical levels?

ATTO last traded at $15.19 (-0.52% on volume of 146,676 shares), positioning the stock -18.16% below its 50-day simple moving average ($18.56) and -19.93% below its 200-day simple moving average ($18.97). Across its 52-week range of $12.94 to $28.00, ATTO sits at the 14.9% percentile with a 14-day RSI of 44.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.29 to $17.09).

ATTO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is ATTO's next earnings date?

Based on SEC filing cadence, Attovia Therapeutics Inc. (ATTO)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is ATTO stock expected to move on earnings?

Volatility modeling currently projects a ±12.5% event move for ATTO, spanning a range between $13.29 and $17.09.

Direct Sub-Reports: ATTO RQD Cockpit ATTO 12M Forecast ATTO Earnings & Move ATTO Dividends & DRIP ATTO Insiders & 13F ATTO Whale Options ATTO Profit Sankey ATTO News & Why

ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ATTO — Attovia Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:15:05Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ATTO scores 44 out of 100, earning a D and the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental cash engine: 10 / 20 (ROIC 0%; FCF yield 0%). Per the Roarable RQD rating and market data, the company shows no measurable return on invested capital or free cash flow yield, so this pillar contributes little support to the score.
Whale / 13F flow: 3 / 20 (institutional accumulation and options positioning). This is the weakest pillar and signals little constructive institutional accumulation in the source data. Holder-level detail is not available in source data.
Insider conviction: 9 / 20 (SEC Form 4 and Congressional PTR cluster flow). Recent news headlines reference Form 4 and option-grant filings, but no trade-level detail is available in source data.
Macro regime fit: 9 / 20 (beta 1.0; sector sensitivity). Per market data, beta is 1.0, meaning the stock is rated as moving in line with the broader market.
Forensic balance sheet: 13 / 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). This is the strongest pillar, indicating a comparatively sound balance sheet relative to the other factors.

For a prospective investor evaluating the stock today, the key implication is that the score is driven by the absence of cash generation and weak institutional support, partially offset by the balance-sheet pillar. The rating does not assess clinical or pipeline prospects, which are not available in source data. Valuation tradeoffs cannot be fully assessed because P/E, EV/EBITDA, and EPS are not available in source data.

Business

Attovia Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, it is classified in this industry with a market capitalization of $0.7B. Products sold, customers served, and revenue model are not available in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025 (filed 2025-12-31)	$0.0M	$0.0M	$0.0M	N/A	N/A	$40.2M	N/A

Per the SEC financials, reported revenue, operating income, and net income for FY 2025 are each $0.0M, and reported cash is $40.2M. Per market data, gross, operating, and net margins are each 0%, and ROIC is 0%. Per the Roarable RQD rating, the forensic balance-sheet pillar cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. Trend analysis across multiple periods is not available in source data, as only one period is provided.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference ATTO, all tagged as market wire with a yellow signal: an upcoming investor-conference participation announcement (Yahoo Finance), a market estimates page (TradingView), a price and quote page (MEXC), an amended CFO option-grant report with no ownership changes (Stock Titan), a short-interest report for September (MarketBeat), and a Form 4 filing report (Investing.com UK). The catalysts are administrative and market-activity oriented; no clinical, regulatory, or commercial milestones are identified in source data. Per the Butterfly Supply-Chain Graph, no supply-chain links or proprietary signals are provided.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream suppliers, downstream customers, and sector correlations beyond the Health Care classification are not available in source data. Second-order bottlenecks cannot be identified from the provided data.

Open Questions

What are the company's clinical, regulatory, and pipeline milestones, and what is their timing?
What is the source of the $0.0M reported revenue, and does the company have any commercial product or collaboration revenue?
What is the company's cash runway given $40.2M in cash and zero reported operating income?
Who are the major institutional holders, and what were the recent 13F position changes?
What do the Form 4 and option-grant filings reveal about insider transactions, beyond the headline references?

ATTO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Attovia Therapeutics Inc. (ATTO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ATTO Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 8h ago

Attovia Therapeutics to Participate in Upcoming Investor Conferences

Yahoo Finance report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 11h ago

Attovia Therapeutics, Inc. Estimates – NASDAQ:ATTO

TradingView report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MEXC • 14h ago

ATTO Price Today: Attovia Therapeutics, Inc. Stock Price, Quote & Chart | MEXC

MEXC report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 17h ago

Attovia Therapeutics (ATTO) amends CFO option-grant report with no ownership changes.

Stock Titan report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 20h ago

Attovia Therapeutics, Inc. (NASDAQ:ATTO) Stock Short Interest Report for September

MarketBeat report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Investing.com UK • 23h ago

Form 4 Attovia Therapeutics For: 8 October By Investing.com

Investing.com UK report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 1d ago

Attovia Therapeutics stock heads into October 8 data presentations

ad-hoc-news.de report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Traders Union • 1d ago

Attovia Therapeutics, Inc. Stock Price Prediction: Today, Tomorrow, Next Week (ATTO)

Traders Union report covering Attovia Therapeutics Inc. (ATTO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ATTO Bull vs. Bear Conversation Board — What's Your Call at $15.19?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ATTO 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $13.44 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ATTO (D • RQD 44/100) a Buy at $15.27?

Welcome to the ATTO (Attovia Therapeutics Inc.) Roar Pit. Current RQD Composite is 44/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $12.22 (-20.0%)

Spot @ $15.27

Pump the brakes on ATTO — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ATTO, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Attovia Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MI MidwestValue Verified K Arena Trader 🐂 BULLISH 🎯 Target: $18.02 (+18.0%)

Spot @ $15.27

ATTO cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ATTO, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $15.27 (52-wk range $12.94 - $28.00), any beat on forward guidance forces shorts and underweight funds to chase.